Glycoprotein VI (GPVI)-functionalized nanoparticles targeting arterial injury sites under physiological flow.
Animals
Atherosclerosis
/ drug therapy
Blood Platelets
/ drug effects
Carotid Arteries
/ drug effects
Carotid Artery Injuries
/ drug therapy
Disease Models, Animal
Humans
Mice
Nanoparticles
/ chemistry
Platelet Activation
/ drug effects
Platelet Adhesiveness
/ drug effects
Platelet Aggregation
/ drug effects
Platelet Membrane Glycoproteins
/ chemistry
Atherothrombosis
Drug delivery
Glycoprotein VI
Hemodynamics
Shear stress
Journal
Nanomedicine : nanotechnology, biology, and medicine
ISSN: 1549-9642
Titre abrégé: Nanomedicine
Pays: United States
ID NLM: 101233142
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
12
03
2020
revised:
14
07
2020
accepted:
15
07
2020
pubmed:
28
7
2020
medline:
8
7
2021
entrez:
27
7
2020
Statut:
ppublish
Résumé
Thrombus formation at athero-thrombotic sites is initiated by the exposure of collagen followed by platelet adhesion mediated by the platelet-specific collagen receptor glycoprotein VI (GPVI). Here, dimeric GPVI was used as a targeting motif to functionalize polymeric nanoparticle-based drug carriers and to show that with proper design, such GPVI-coated nanoparticles (GPNs) can efficiently and specifically target arterial injury sites while withstanding physiological flow. In a microfluidic model, under physiological shear levels (1-40 dyne/cm
Identifiants
pubmed: 32712174
pii: S1549-9634(20)30128-3
doi: 10.1016/j.nano.2020.102274
pii:
doi:
Substances chimiques
Platelet Membrane Glycoproteins
0
platelet membrane glycoprotein VI
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102274Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.